Endo Will Pay More Than 8 Billion Dollars For Par Pharmaceutical
Endo International company intends to acquire Par Pharmaceutical Holdings US drugmakers for 8.05 billion dollars. The boards of directors of both companies have approved that the transaction is planned.
Buying Par Pharmaceutical will allow Endo to strengthen its position in the market of generic drugs, and significantly expand the portfolio of manufactured products. After adding Par Pharmaceutical, Endo will get the rights for 100 registered generic drugs, whose production is established at four sites.
Income from the sale of generic drugs is amounted to about 40% of the profits Endo in 2014. Then the company earned $ 2.88 billion. The profit of Par Pharmaceutical in the past year reached1.28 billion dollars.
- AbbVie Paid Shire 1,6 Billion For Failed Acquistion
- Bristol-Myers Squibb announced the acquisition Flexus for $ 1.25 billion
- Actavis Completed The Acquisition Of Allergan